Pralmorelin may provide a stronger, more aggressive growth hormone response, while Ipamorelin is often viewed as a more balanced and selective option
This section summarises published findings on investigational and clinical Tirzepatide research , not instructions or expectations for use of this product
Both semaglutide and tirzepatide have been used as addon therapies to insulin in patients with T1D and obesity, producing additional HbA1c reductions of up to 0.54% and 0.68%, respectively [82, 83]
PMID 26462967
Both formulations are generally well-tolerated with few serious side effects reported in long-term follow up studies
Biochemistry 40: 90409048 Bruggeman Q, Mazubert C, Prunier F, Lugan R, Chan KX, Phua SY, Pogson BJ, Krieger-Liszkay A, Delarue M, Benhamed M, et al